Bloomington, IN/ Paris, France - February 9, 2011 -- The ultimate goal of a drug development project is reaching the clinic with quality product on time and on budget. Creating a chain of clinical phase services connected by collaboration and transparency to deliver such results is the backbone behind the partnership between North American based BioConvergence and European based Creapharm. Through this joint effort we build synergies for our customers that lower costs, reduce risks, and increase control of projects. Our partnership unites excellence in pharmaceutical services and provides integrated, customized services with innovative, transparent, and effective solutions.
BioConvergence and Creapharm have combined their strengths to offer the biotech and pharmaceutical industries experienced talent and a variety of services required during preclinical and early stage clinical phases. This partnership will enable clients to expand their pharmaceutical development and clinical supply support without adding resources and costs normally associated with managing multiple partners. Our Transatlantic Bridge provides access to North America from Europe and Europe from North America through a single point of contact who manages all aspects of the project including contract management, project management, product development, production, testing, and clinical supply services. Through our innovative and customized solutions, we manage critical path initiatives utilizing our collective geographic presence and regulatory knowledge. Clients worldwide will acquire project information using E-Transparency® System, a proprietary secure portal providing real-time access to development, production, supply chain, and quality data. Pharmaceutical and biotech companies who increasingly develop new therapies targeted for clinical research and conduct clinical trials in the US and Europe will be a primary focus of this Transatlantic Bridge.
“I’m pleased to announce that through our collaboration with Creapharm, we will deliver new sourcing, contracting, and management options designed to optimize early clinical development, production, testing, and supply chain design and execution. By doing so, our clients will realize results they value,” Alisa Wright, CEO BioConvergence LLC.
“Creapharm is one of the leaders in Europe for pharmaceutical development and clinical supplies, but until now has had no operations in North America, which is and will remain the number one territory for clinical studies. Through our collaboration with BioConvergence I am pleased to announce that we can now provide to our European clients a “Transatlantic Bridge”, a seamless extended supply service of the highest quality for clinical studies in North America”, Michel Pautrat, CEO Creapharm Europe.
About BioConvergence LLC
BioConvergence is a small, woman-owned business in Indiana providing services for the pharmaceutical and biotech industries in support of product development and clinical supplies. They are a leader in the industry offering a secure E Transparency® System giving clients access to their records 24/7 encompassing real-time environmental monitoring data, product receipts, processing, and domestic and international shipments in addition to SOPs and quality-related reports. With the strength of a very experienced team, BioConvergence has successfully completed clinical production from master batch record development through QA release in less than 3 weeks, reduced lyophilization cycle length by 50%, and managed the clinical supply chains of over 4,000 raw materials and clinical products for clients of all sizes. To learn more about BioConvergence and its services visit www.creapharm-bioc.com or call +1 812 961 1700.
About Creapharm
Creapharm is a leading development and clinical supply company in Europe. Creapharm offers phrmacedutical development and Phase I-IV clinical manufacturing, packaging and labeling as well as clinical inventory management, and cold chain distribution with a large network of worldwide depots to meet client’s diverse clinical trial needs. Creapharm has produced over 300 lyophilized clinical batches relating to about 50different projects, has labeled and packed over 6,000 clinical batches and has made close to 200 000shipments to investigation centers since its inception. Creapharm has locations in Europe, one of which is dedicated to injectables development and production.. To learn more about Creapharm and its services visit www.creapharm-bioc.com or call +33(0)4 73 33 72 40
